ArticleDrug, healthcare and patient safety2025

Comparing Out-of-Pocket Costs and Health-Related Quality of Life Between Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.

Sisi Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.